A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...